Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
ABVX
ABIVAX Société Anonyme
NASDAQGM
Biotechnology
France
$114.79
▲
+0.75 (+0.66%)
POST
—
OPEN
$114.15
HIGH
$115.33
LOW
$112.78
PREV CLOSE
$114.04
VOLUME
489.8K
0.33x avg
MARKET CAP
$10.02B
DAY RANGE
$112.78
$115.33
P/E (TTM)
—
Fwd -36.5
EPS (TTM)
-5.35
DIV YIELD
—
52W HIGH
$148.83
-22.9%
52W LOW
$69.81
+64.4%
BETA
-0.23
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$114.56
-0.23
(-0.20%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
ABVX
$114.79
▲
+0.66%
Chart
Valuation
Financials
Peers
News
ABVX · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-ON
252 BARS · +30.4% YOY
1-year price chart. Started at 88.03, currently 114.79, up 30.4 percent. Range 72.50 to 145.31 over 252 data points.
2025-09-05
$88.03 → $114.79 (+30.4%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$46.69
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: strong-sell
· peers $46.69 (-59.3%)
Peers:
AEIS PE52
ALGM PE523
APH PE41
AAOI
ARW PE14
ALAB PE152
CLS PE32
CVE PE12
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$336.1M
-$161.1M
—
$584.3M
2024-12
—
-$176.2M
-$154.1M
—
$205.2M
2023-12
—
-$147.7M
-$97.1M
—
$327.1M
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
AEIS
ALGM
APH
AAOI
ARW
ALAB
CLS
CVE
CLX
COHR
NEWS
Recent News (past 14 days)
CALM
10 HEADLINES · LAST 14 DAYS
NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
GlobeNewswire · 2026-09-01
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
Business Wire · 2026-08-04
AbbVie Q2 Earnings Call Highlights
MarketBeat · 2026-07-31
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
GlobeNewswire · 2026-07-30
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
PR Newswire · 2026-07-30
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants
Business Wire · 2026-07-29
ABIVAX Société Anonyme (ENXTPA:ABVX) Adds Commercial Leaders, Is The Upside Already Priced In?
Simply Wall St. · 2026-07-26
Abivax (ENXTPA:ABVX) Adds Commercial Leaders And Signs Valerio R And D Deal
Simply Wall St. · 2026-07-25